GaRP Trial Update:

Kylie Wilkie, Clinical Trials Manager

Garp trial- Summary

- On track for recruitment of Stage 1 participants (n=90) by end of 1Q23
- No Significant Adverse Events
- Strong interest in the trial and support from gastroenterologists.
- Trial protocol changes to enhance participation have been approved by Bellberry HREC, currently being reviewed by RMH HREC

Dose Determination and Efficacy Evaluation of the Gastrointestinal ReProgramming (GaRP) Dietary supplement in IBS patients

- A Randomized, Double-blind, Placebo-controlled clinical trial enrolling 200 IBS participants
- Stage 1 (n=90, 1Q23)
  - To determine the safety and efficacy of two different doses of GaRP in IBS patients after 8 weeks of intervention.
  - To determine the dose which provides acceptable safety and a preliminary indication of efficacy for use in the single dose stage 2 cohort .
- Stage 2 (n=110)
  - To confirm efficacy of the dose identified in Stage 1 by at least a 20% improvement in IBS-SSS score.
- No Serious Adverse Events
- 6 sites currently enrolling - including Royal Melbourne Hospital
- Over 3000 people have registered their interest in the trial

Current Study Flow



Updated Study flow



Garp trial- Summary

- On track for Recruitment of Stage 1 participants (n=90) by end of 1Q23
- No Significant Adverse Events
- Strong interest in the trial and support from gastroenterologists.
- Protocol changes to enhance participation have been approved by Bellberry HREC, currently being reviewed by RMH HREC